D-Index & Metrics Best Publications
Research.com 2022 Best Scientist Award Badge
Microbiology
Greece
2022

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Microbiology D-index 133 Citations 68,587 468 World Ranking 14 National Ranking 1
Medicine D-index 155 Citations 95,600 921 World Ranking 342 National Ranking 2
Best Scientists D-index 159 Citations 104,186 721 World Ranking 876 National Ranking 2

Research.com Recognitions

Awards & Achievements

2022 - Research.com Best Scientist Award

2022 - Research.com Medicine in Greece Leader Award

2022 - Research.com Microbiology in Greece Leader Award

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Surgery
  • Antibiotics

His primary areas of study are Internal medicine, Antibiotics, Antibacterial agent, Microbiology and Acinetobacter baumannii. His biological study spans a wide range of topics, including Bacteremia and Surgery. His Antibiotics research includes elements of Pharmacotherapy, Drug resistance and Intensive care medicine.

The Antibacterial agent study which covers Pharmacology that intersects with Aminoglycoside. Matthew E. Falagas interconnects Klebsiella pneumoniae and Gram-negative bacteria in the investigation of issues within Microbiology. His Acinetobacter baumannii research is multidisciplinary, incorporating perspectives in Case-control study and Colistin.

His most cited work include:

  • Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance (4863 citations)
  • Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance (4863 citations)
  • Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses (1479 citations)

What are the main themes of his work throughout his whole career to date?

Matthew E. Falagas spends much of his time researching Internal medicine, Surgery, Intensive care medicine, Antibiotics and Antibacterial agent. His biological study spans a wide range of topics, including Bacteremia, Ciprofloxacin and Incidence. The study incorporates disciplines such as Pharmacotherapy and Epidemiology in addition to Intensive care medicine.

His Antibiotics study combines topics from a wide range of disciplines, such as Antimicrobial and Drug resistance. The Meta-analysis study combines topics in areas such as Relative risk and Confidence interval. His research integrates issues of Nephrotoxicity, Acinetobacter baumannii, Polymyxin and Polymyxin B in his study of Colistin.

He most often published in these fields:

  • Internal medicine (59.35%)
  • Surgery (47.56%)
  • Intensive care medicine (36.28%)

What were the highlights of his more recent work (between 2012-2021)?

  • Internal medicine (59.35%)
  • Antibiotics (33.94%)
  • Intensive care medicine (36.28%)

In recent papers he was focusing on the following fields of study:

Matthew E. Falagas focuses on Internal medicine, Antibiotics, Intensive care medicine, Meta-analysis and Microbiology. The various areas that Matthew E. Falagas examines in his Internal medicine study include Bacteremia and Surgery. In general Antibiotics study, his work on Multiple drug resistance often relates to the realm of Bronchiectasis, thereby connecting several areas of interest.

His work deals with themes such as Immunology and Acinetobacter, which intersect with Multiple drug resistance. His work investigates the relationship between Intensive care medicine and topics such as Drug resistance that intersect with problems in Methicillin-resistant Staphylococcus aureus and Staphylococcus aureus. As a member of one scientific family, Matthew E. Falagas mostly works in the field of Microbiology, focusing on Enterobacteriaceae and, on occasion, Pharmacotherapy and Klebsiella pneumoniae.

Between 2012 and 2021, his most popular works were:

  • Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. (296 citations)
  • Antibiotic Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae: Systematic Evaluation of the Available Evidence (234 citations)
  • Clinical Outcomes With Extended or Continuous Versus Short-term Intravenous Infusion of Carbapenems and Piperacillin/Tazobactam: A Systematic Review and Meta-analysis (207 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Surgery
  • Antibiotics

His scientific interests lie mostly in Internal medicine, Meta-analysis, Intensive care medicine, Randomized controlled trial and Surgery. His Internal medicine study combines topics in areas such as Bacteremia and Pseudomonas aeruginosa. His research in Intensive care medicine intersects with topics in Multiple drug resistance, Antibiotics, University hospital, Pneumonia and Acinetobacter baumannii.

Matthew E. Falagas combines subjects such as Plazomicin and Adverse effect with his study of Antibiotics. His work carried out in the field of Randomized controlled trial brings together such families of science as Pharmacodynamics and Pediatrics. Matthew E. Falagas has included themes like Colistin and Microbiology in his Vancomycin study.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

A-P Magiorakos;A Srinivasan;R B Carey;Y Carmeli.
Clinical Microbiology and Infection (2012)

7485 Citations

Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses

Matthew E. Falagas;Eleni I. Pitsouni;George A. Malietzis;Georgios Pappas.
The FASEB Journal (2007)

2352 Citations

Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram-Negative Bacterial Infections

Matthew E. Falagas;Matthew E. Falagas;Sofia K. Kasiakou;Louis D. Saravolatz.
Clinical Infectious Diseases (2005)

1663 Citations

Toxoplasmosis snapshots: Global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis

Georgios Pappas;Nikos Roussos;Matthew E. Falagas;Matthew E. Falagas.
International Journal for Parasitology (2009)

982 Citations

Obesity and infection

Matthew E Falagas;Matthew E Falagas;Maria Kompoti.
Lancet Infectious Diseases (2006)

787 Citations

Toxicity of polymyxins: a systematic review of the evidence from old and recent studies

Matthew E Falagas;Matthew E Falagas;Sofia K Kasiakou.
Critical Care (2006)

786 Citations

Current control and treatment of multidrug-resistant Acinetobacter baumannii infections

Drosos E Karageorgopoulos;Matthew E Falagas;Matthew E Falagas.
Lancet Infectious Diseases (2008)

644 Citations

Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review.

Petros I Rafailidis;Eleni G Mourtzoukou;Ioannis C Varbobitis;Matthew E Falagas;Matthew E Falagas.
Virology Journal (2008)

605 Citations

Extended-spectrum β-lactamase-producing organisms

M.E. Falagas;M.E. Falagas;D.E. Karageorgopoulos.
Journal of Hospital Infection (2009)

594 Citations

The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa.

Matthew E. Falagas;Matthew E. Falagas;Patra K. Koletsi;Ioannis A. Bliziotis.
Journal of Medical Microbiology (2006)

567 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Matthew E. Falagas

Matteo Bassetti

Matteo Bassetti

University of Genoa

Publications: 116

Jason A. Roberts

Jason A. Roberts

Royal Brisbane and Women's Hospital

Publications: 111

David L. Paterson

David L. Paterson

University of Queensland

Publications: 105

Jeffrey Lipman

Jeffrey Lipman

Royal Brisbane and Women's Hospital

Publications: 92

Roger L. Nation

Roger L. Nation

Monash University

Publications: 88

Jesús Rodríguez-Baño

Jesús Rodríguez-Baño

University of Seville

Publications: 85

Robert A. Bonomo

Robert A. Bonomo

United States Department of Veterans Affairs

Publications: 82

Leonard Leibovici

Leonard Leibovici

Rabin Medical Center

Publications: 80

Mical Paul

Mical Paul

Rambam Health Care Campus

Publications: 73

Antoni Torres

Antoni Torres

University of Barcelona

Publications: 70

Jordi Carratalà

Jordi Carratalà

University of Barcelona

Publications: 67

Antonio Oliver

Antonio Oliver

Instituto de Salud Carlos III

Publications: 63

Helen Giamarellou

Helen Giamarellou

Athens State University

Publications: 62

David P. Nicolau

David P. Nicolau

Hartford Hospital

Publications: 61

Álvaro Pascual

Álvaro Pascual

Spanish National Research Council

Publications: 59

Marin H. Kollef

Marin H. Kollef

Washington University in St. Louis

Publications: 59

Trending Scientists

Yvan Labiche

Yvan Labiche

Carleton University

Lorenzo Torresani

Lorenzo Torresani

Facebook (United States)

Stijn Van Nieuwerburgh

Stijn Van Nieuwerburgh

Columbia University

Ming J. Zuo

Ming J. Zuo

University of Alberta

Neil J. Balmforth

Neil J. Balmforth

University of British Columbia

Jean Schmittbuhl

Jean Schmittbuhl

University of Strasbourg

Haisheng Chen

Haisheng Chen

Chinese Academy of Sciences

Jorge G. Zornberg

Jorge G. Zornberg

The University of Texas at Austin

Jonathan P. Zehr

Jonathan P. Zehr

University of California, Santa Cruz

Andréa Dessen

Andréa Dessen

Brazilian Biosciences National Laboratory

B. V. Venkataram Prasad

B. V. Venkataram Prasad

Baylor College of Medicine

Sandip Patel

Sandip Patel

University College London

William B. Krabill

William B. Krabill

Goddard Space Flight Center

Christoph Laske

Christoph Laske

German Center for Neurodegenerative Diseases

Predrag Petrovic

Predrag Petrovic

Karolinska Institute

Karl A. Nath

Karl A. Nath

Mayo Clinic

Something went wrong. Please try again later.